1. HBW Insight
  2. >>Leadership

Would An Independent Analysis Of US FDA's Pandemic Response Find Transformative Effect?

Group of outside experts could help the agency determine the pandemic-inspired practices and regulatory changes to keep, former commissioner von Eschenbach says.

Screenshot from FDLI Annual Conference of former commissioners' discussion
Former FDA commissioners Andrew von Eschenbach, top left, Robert Califf, bottom left, and Mark McClellan, bottom right, discuss how the pandemic changed the agency with FDLI president and CEO Amy Comstock Rick. • Source: FDLI annual conference screenshot

A former US Food and Drug Administration commissioner, Andrew von Eschenbach, suggests an external group may offer the best chance for the agency to determine the best lessons learned by lessons from the coronavirus pandemic.

During an 18 May Food and Drug Law Institute Annual Conference session, von Eschenbach, president of Samaritan Health Initiatives, said...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

IBA Interactive Policy Map Is Call To Action As Cosmetics Industry Braces For Myriad Of State Bills

 
• By Eileen Francis

The Independent Beauty Association has launched an interactive Policy Map tracking state and federal bills and filtering by state or topic, pinpointing bills of great priority.

US Consumer Health Executive News: Perrigo, SunsolveMD, Godreg, BRC Therapeutics

 
• By Malcolm Spicer

Winterman moves from AstraZeneca to lead Perrigo supply operations; SunsolveMD fashions a brand ambassador in Elsa Hosk; Former P&G marketing exec Davis-Artis joins Godrej; and Epidiolex developer Wright advises BRC Th

People On The Move: Appointments At Klosterfrau, Haleon, Opella

 
• By Tom Gallen

A round-up of the latest consumer health industry appointments: Kloserfrau makes changes to management in Germany; Haleon hires Pakistan head; Opella names Americas leader.

Over The Counter: Driving Innovation In France’s Self-Care Market, With NèreS’ Luc Besançon

 
• By David Ridley

HBW Insight speaks to NèreS' executive director Luc Besançon about the key issues facing France's self-care industry, especially Rx-to-OTC switch and the revised Urban Wastewater Treatment Directive.

More from HBW Insight

FDA’s FY 2026 Budget Request Lacks New Policy Proposals

 
• By Sue Sutter

The White House requested $6.8bn for the FDA, down 3.9% from the current funding level, but does not propose any legislative changes. In previous years, the agency used the budget process to seek statutory fixes specific to generic drugs and shortages.

House Appropriators’ $3.2Bn For FDA In FY 2026 Includes More Non-User Fee Funds Than Requested

 
• By Sue Sutter and Derrick Gingery

A US House bill would give the FDA $33.1m more in budget authority than requested by the Trump Administration for fiscal year 2026. The measure was sent to the full House Appropriations committee on a party-line vote.

EU Pharma Reform: Council Proposes Rx Exemption For Topical Antimicrobials

 
• By David Ridley

The EU Council has introduced a key amendment to Article 51 (para 1, point e) of the new pharma directive: “A medicinal product shall be subject to medical prescription where it is an antimicrobial, unless intended for topical use.”